评论
打印
本期内容：
Eli Lilly said that a clinical trial for a new drug to slow the onset of Alzheimer’s had failed. The drug, solanezumab, was tested on patients with mild cases of Alzheimer’s, who showed only a slight improvement after 18 months of treatment. The experiment had been closely watched by medical researchers and hopes were high that solanezumab would be the first drug approved to treat the disease.
Clinical trial: 临床试验
Onset：开始
Alzheimer‘s： 老年痴呆症
想了解更多信息，请关注:
新浪微博：教书匠小夏
微信公众号：教书匠小夏
